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SummAry
The aim of this study is to investigate whether, in addition to intratympanic steroid therapy, additional hyperbaric oxygen therapy (hBoT) 
sessions per day (twice a day for 5 days) is more useful than one session per day for 10 days in patients affected by severe and profound idi-
opathic sudden sensorineural hearing loss (iSSnhl). A total of 55 patients affected by unilateral severe and profound iSSnhl were recruited. 
Two protocols were adopted. in the first, 27 patients (13 with profound and 14 with severe hearing loss) underwent one session of hBoT per 
day for 10 days, 6 days a week. An hBoT session comprised a period of 14 minutes air compression followed by 90 min at 2.4 atm absolute 
(ATA) followed by a decompression period of 15 min in oxygen. Patients breathed 100% oxygen through an appropriate mask checked for 
leaks. Patients were given 0.4 ml of 62.5 mg/ml of intratympanic prednisolone during the first three days of the protocol. in the second proto-
col, 28 patients (10 with profound and 18 with severe hearing loss) received 10 sessions of hBoT, twice a day for five days, 2.4 ATA 90 min 
100% oxygen. The intratympanic injections of prednisolone were given between the two sessions of hBoT during the first three days of the 
protocol. Since there were no significant differences in hearing outcomes between the two protocols, the present study shows that the protocol 
of two sessions of hBoT per day is a valid treatment and equally effective as the one hBoT session per day, but with shorter treatment time.
Key wordS: Deafness • Prednisolone • Hypoxia • Pure-tone average • Cochlea • Inner ear
riASSunTo
La finalità dello studio è stata quella di investigare se, in pazienti affetti da ipoacusia improvvisa di grado severo e profondo, un numero 
maggiore di sedute giornaliere di ossigenoterapia iperbarica (due volte al giorno per 5 giorni) in associazione alla terapia steroidea in-
tratimpanica, risulti più efficace della tradizionale sessione giornaliera di ossigenoterapia iperbarica effettuata per 10 giorni. 55 pazienti 
affetti da ipoacusia idiopatica unilaterale severa e profonda sono stati reclutati nello studio. Sono stati utilizzati due diversi protocolli 
terapeutici: il primo è consistito di 27 pazienti (13 con ipoacusia improvvisa profonda e 14 con ipoacusia improvvisa severa) che sono 
stati sottoposti ad una sessione di camera iperbarica giornaliera per un totale di 10 giorni (sei giorni a settimana). La sessione di camera 
iperbarica è consistita in un periodo di 14 minuti di compressione in aria seguiti da un periodo di trattamento a 2,4 atmosfere assolute 
(ATA) per 90 minuti e poi ad un successivo periodo di decompressione di 15 minuti in ossigeno. I pazienti hanno respirato ossigeno al 
100% attraverso un’apposita maschera. Ai pazienti è stata somministrata una dose intratimpanica di 0.4 ml di prednisolone a 62,5 mg/
ml durante i primi tre giorni del protocollo. Il secondo protocollo è consistito di 28 pazienti (10 con ipoacusia profonde 18 con ipoacusia 
severa) che hanno ricevuto 10 trattamenti di camera iperbarica 2 volte al giorno 2,4 ATA, 90 minuti con ossigeno al 100%. Le infiltrazioni 
intratimpaniche di prednisolone sono state effettuate nel tempo intercorrente tra le due sessioni giornaliere di camera iperbarica durante i 
primi tre giorni del protocollo. Lo studio, non avendo evidenziato alcuna significativa differenza in termini di risultati uditivi tra i due pro-
tocolli sperimentali, permette di considerare il protocollo con la doppia sessione giornaliera di camera iperbarica una valida alternativa 
alla sessione unica giornaliera garantendo una significativa riduzione della durata complessiva della terapia.
PArole ChiAve: Sordità • Prednisolone • Ipossia • Pure-tone average • Coclea • Orecchio interno
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Introduction
idiopathic sudden sensorineural hearing loss (iSSnhl) 
is defined by the uS national institute for deafness and 
Communication disorders as a decline in hearing over 3 
days or less, affecting three or more contiguous audio-
metric frequencies by 30 dB or more, with no identifiable 
aetiology 1. The treatment of patients with iSSnhl varies 
at different otological centres, but corticosteroids are con-
sidered the gold standard therapy 2.
in the literature a number of different regimens have been 
proposed as therapy for iSSnhl including vasodilators, 
anticoagulants, antioxidants, plasma expanders, antivi-
ral agents, h.e.l.P. apheresis, carbogen and corticoster-
oids 3-5. hyperbaric oxygen therapy (hBoT) is also used 
in iSSnhl to increase the partial oxygen pressure and to 
improve the blood profile and microcirculation. Solubil-
ity of gases in liquids depends on pressure, and during 
hBoT, due to the increased external pressure, a much 
larger amount of oxygen enters the blood from the alve-
oli. Blood with a higher concentration of oxygen cross-
ing from the thin alveolar walls is transported through the 
bloodstream to all parts of the body. The more dissolved 
oxygen is in the blood, the better it gets into the organs 
and tissues 6 7.
in 2002 Aslan et al. demonstrated the efficacy of one daily 
hBoT session in addition to conventional treatment mo-
dalities for iSSnhl 8. in 2012, the efficacy of one daily 
session of hBoT was demonstrated in association with 
short duration intratympanic steroid therapy (iTS) in pa-
tients affected by severe and profound iSSnhl known to 
be less responsive to systemic steroid treatment 9.
it is also known that an increase in hyperbaric sessions 
per day significantly improves soft tissue and bone recov-
ery, wound healing, infection control, ulcers and compro-
mised flap recovery 10 11. in 2011, Thom et al. demonstrat-
ed that hBoT can mobilize bone marrow stem cells by 
stimulating nitric oxide synthase. it was found that nitric 
oxide synthase activity is acutely increased in platelets 
following hBoT that remained elevated for at least 20 
hours. hBoT stimulates vasculogenic stem cell mobiliza-
tion from bone marrow of diabetics, and more cells are 
recruited to skin wounds 12.
The aim of this study is to investigate whether, in addition 
to iTS, a higher number of hBoT sessions per day (twice 
a day for 5 days) is more useful than one session per day 
for 10 days in patients affected by severe and profound 
iSSnhl.
Materials and methods
A total of 55 patients affected by unilateral severe and 
profound iSSnhl who were examined by the enT 
emergency room staff of the department of Sensory 
organs of Sapienza università di roma from Janu-
ary 2012 to december 2013 were enrolled in this ran-
domised pilot study. Severe iSSnhl is defined by a 
pure-tone average (PTA) between 70 and 90  dB and 
profound iSSnhl by a PTA > 90 dB. All patients met 
the following inclusion criteria: age between 19 and 85 
years, time elapsed between the onset of iSSnhl and 
beginning of therapy not exceeding 15 days, no previ-
ous therapy for iSSnhl, no surgery affecting the ip-
silateral ear and no retrocochlear disease, no acoustic 
trauma and no autoimmune or fluctuating hearing loss. 
The exclusion criteria were: chronic bronco-pulmonary 
obstructive syndrome, emphysema, sinusitis, seizure 
syndrome, pregnancy and claustrophobia in a hyper-
baric environment. informed written consent was ob-
tained from each patient.
Treatment strategies
Two protocols were adopted. The first (hBoT1) consisted 
of 27 patients (13 with profound and 14 with severe sud-
den hearing loss) who underwent one session of hBoT 
per day for 10 days in a multi-place hyperbaric chamber, 
6 days a week. A hBoT session comprised a period of 14 
min compression in air followed by a treatment period at 
2.4 atm absolute (ATA) for 90 min and then a decompres-
sion period of 15 min in oxygen. Patients breathed 100% 
oxygen through an appropriate mask checked for leaks. 
Patients were given 0.4 ml of 62.5 mg/ml of intratympan-
ic prednisolone (deltacortene Sol® Bruno Farmaceutici, 
rome, italy) before the hBoT session during the first 
three days of the protocol. The iT injection technique has 
been reported 13.
The second protocol (hBoT2) consisted of 28 patients 
(10 with profound and 18 with severe sudden hearing 
loss) who received 10 sessions of hBoT, twice a day for 
five days, 2.4 ATA 90 min 100% oxygen in a multi-place 
hyperbaric chamber. intratympanic injections of predni-
solone were given between the two sessions of hBoT 
during the first three days of the protocol. within each 
protocol, patients were homogenous according to age, sex 
and PTA.
Standard assessment
The standard assessment includes audiometric testing 
PTA and impedance audiometry, vestibular tests, routine 
serological test, coagulation, high resolution CT of tem-
poral bone and mri of the brain (specifically of the cer-
ebellopontine angle with gadolinium).
Audiological evaluation and hearing improvement
All patients underwent evaluation of PTA immediately 
before the beginning of the treatment and one day after 
the last session of hBoT (11 days after hBoT1 treatment 
and 6 days after hBoT2). The results were compared. 
PTA was calculated as the mean of thresholds at the six 
frequencies (250, 500, 1000, 2000, 4000 and 8000 hz). 
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Thresholds that could not be measured due to the limit 
of the audiometric equipment were “dummy coded” with 
the highest test level of audiometric equipment, as sug-
gested in a recent study 14 15. in these cases they were set 
at 130 dB.
Criteria adopted for evaluating audiological improvement 
were based on those used by Furuhashi et al. 16 who classi-
fied the outcomes as complete recovery, marked improve-
ment, partial improvement, or non-recovery. Successful 
treatment is defined as complete recovery or marked 
improvement in PTA at six frequencies (250, 500, 1000, 
2000, 4000 and 8000 hz) (Table i).
Table I. Criteria used to define audiological improvement.
Hearing Outcome Furuhashi’s criteria
Complete recovery* PTA ≤ 25 dB or identical to the contralateral, 
non-affected ear
Marked improvement* PTA improvement > 30 dB
Slight improvement PTA improvement between 10 and 30 dB
No recovery PTA improvement < 10 dB
* Successful treatment: complete recovery and marked recovery.
Statistical analysis
Statistical analysis on PTA values was performed using 
AnovA two-way repeated measurements. Bonferroni 
post-hoc test was performed for the analysis of statisti-
cally significant interactions. unpaired t-test was per-
formed in the comparison between the two groups in the 
pre-treatment phase. Fisher’s exact test was performed 
in the comparison of treatment outcomes between and 
within groups (hBoT1 and hBoT2 severe and profound 
hearing loss).
Results
PTA
The frequency averages of patients treated with the two 
protocols, before and after the therapy, is shown in Fig-
ure 1.
Any statistically significant difference of PTA values was 
observed comparing the pre-treatment phase between the 
two groups hBoT1 and hBoT2 (p = 0.17).
in all patients the comparison of PTA before and after 
treatment showed a statistically significant reduction 
(p  <  0.0001). The average PTA decreased for hBoT1 
from 92.04 ± 18.6 to 62.65 ± 29.14, and for hBoT2 from 
85.53 ± 16.3 to 56.07 ± 29.19 with a statistical signifi-
cance of p < 0.001 for each protocol (Fig. 2). Comparing 
the results within the severe and profound hearing loss 
group a statistically significant reduction of PTA was ob-
served, while no significant difference regarding the two 
protocols was seen (p = 0.27) (Fig. 3).
Fig. 1. Threshold average of frequencies in the patients treated with the 
two protocols. Pre: before therapy; post: at the end of therapy.
Fig. 2. Average PTA for each protocol before and after treatment.
Fig. 3. Mean PTA based on the two protocols in profound and severe hear-
ing loss.
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Clinical evaluation of hearing outcomes
According to the audiological criteria of Furuhashi, there 
was no significant difference between the two protocols 
(p = 0.58) (Table ii).
Table II. Audiological results according to Furuhashi’s criteria.
Hearing outcomes 
(Furuhashi’s criteria)
Severe SSNHL Profound SSNHL
HBOT1
n = 14
HBOT2
n = 18
HBOT1
n = 13
HBOT2
n = 10
Successful treatment
Unsuccessful treatment
10
4
14
4
6
7
5
5
no significant differences were observed in the audio-
metric division in severe or profound hearing loss (severe 
p = 0.7; profound p = 1) and between the two experimen-
tal groups (hBoT1 p = 0.25; hBoT2 p = 0.21) (Fig. 4).
Discussion
in the last few years, iTS injection has been considered 
a good treatment for iSSnhl as it permits the greatest 
possible intra-cochlear concentration of cortisone, with-
out the risk of adverse systemic effects, although the exact 
mechanism in still unclear. in the literature, iTS injection 
is favoured not also as a first line therapy, but also as sal-
vage therapy 17.
The logical basis for the use of hBoT in iSSnhl is 
linked to the pathogenetic hypothesis. whatever the ae-
tiology –  vascular, viral, autoimmune, or metabolic  – 
the final event triggering cochlear damage is always the 
same: hypoxia. Accumulation of Co
2
 leads to anaerobic 
glycolysis, acidosis, tissue oedema, a further reduction of 
blood flow and ultimately to increasingly serious oxygen 
debt, with evident consequences on homeostasis of inner 
and outer hair cells and labyrinthine fluids. Furthermore, 
hBoT has been shown to provide a significant additional 
effect when used in combination with a steroid therapy 
for iSSnhl 9.
To improve hearing outcomes in patients affected by iSS-
nhl, the present study proposed an increase in the fre-
quency of hBoT sessions per day, as in the treatment of 
some other pathologies (crush syndrome, soft tissue in-
fections, burns, etc.).
regardless of the severity of the hearing loss, the results 
obtained show that patients with severe or profound hear-
ing loss respond similarly to both protocols of iTS injec-
tion associated with one or two hBoT sessions per day. 
Considering the two protocols individually, both demon-
strated the efficacy of the treatment for iSSnhl. The per-
centages of recovery and the values of PTA do not show 
any different effects with one session of hBoT per day or 
two, in combination with iTS.
Possible complications during hBoT include barotrau-
matic lesions (middle ear, nasal sinuses, inner ear, lung, 
teeth), oxygen toxicity (central nervous system, lung), 
confinement anxiety and ocular effects (myopia, cataract 
growth)  18. There are also some potential disadvantages 
to iTS such as otitis media, transient vertigo, otomyco-
sis, perforations of tympanic membrane, myringitis 19 and 
pneumolabyrinth 20. in our study, no patient experienced 
these side effects.
Since there were no significant differences in hearing 
outcomes between the two regimens, the present study 
demonstrates that a protocol of two sessions of hBoT per 
day is a valid treatment and equally effective as the one 
hBoT session per day, with a shorter duration, and that 
it may also be less stressful and more acceptable for the 
patient. The protocol of two hBoT sessions per day could 
be more flexible and adaptable to the needs of patients.
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